JP6918365B2 - 脂質化ｐｓａ組成物および方法 - Google Patents

脂質化ｐｓａ組成物および方法 Download PDF

Info

Publication number
JP6918365B2
JP6918365B2 JP2018508753A JP2018508753A JP6918365B2 JP 6918365 B2 JP6918365 B2 JP 6918365B2 JP 2018508753 A JP2018508753 A JP 2018508753A JP 2018508753 A JP2018508753 A JP 2018508753A JP 6918365 B2 JP6918365 B2 JP 6918365B2
Authority
JP
Japan
Prior art keywords
psa
lipidized
polysaccharide
isolated
glycolipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018508753A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528303A (ja
JP2018528303A5 (enExample
Inventor
ソンワン・オ
デニス・エルトゥルク−ハスデミア
デニス・エル・カスパー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of JP2018528303A publication Critical patent/JP2018528303A/ja
Publication of JP2018528303A5 publication Critical patent/JP2018528303A5/ja
Priority to JP2021116481A priority Critical patent/JP2021178967A/ja
Application granted granted Critical
Publication of JP6918365B2 publication Critical patent/JP6918365B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04—Phosphates; Phosphites; Polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Sustainable Development (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018508753A 2015-08-19 2016-08-19 脂質化ｐｓａ組成物および方法 Expired - Fee Related JP6918365B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021116481A JP2021178967A (ja) 2015-08-19 2021-07-14 脂質化ｐｓａ組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562207360P 2015-08-19 2015-08-19
US62/207,360 2015-08-19
PCT/US2016/047787 WO2017031431A1 (en) 2015-08-19 2016-08-19 Lipidated psa compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021116481A Division JP2021178967A (ja) 2015-08-19 2021-07-14 脂質化ｐｓａ組成物および方法

Publications (3)

Publication Number Publication Date
JP2018528303A JP2018528303A (ja) 2018-09-27
JP2018528303A5 JP2018528303A5 (enExample) 2019-10-03
JP6918365B2 true JP6918365B2 (ja) 2021-08-11

Family

ID=58051049

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018508753A Expired - Fee Related JP6918365B2 (ja) 2015-08-19 2016-08-19 脂質化ｐｓａ組成物および方法
JP2021116481A Pending JP2021178967A (ja) 2015-08-19 2021-07-14 脂質化ｐｓａ組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021116481A Pending JP2021178967A (ja) 2015-08-19 2021-07-14 脂質化ｐｓａ組成物および方法

Country Status (5)

Country Link
US (2) US10857177B2 (enExample)
EP (1) EP3337321A4 (enExample)
JP (2) JP6918365B2 (enExample)
CN (2) CN108135167B (enExample)
WO (1) WO2017031431A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108135167B (zh) 2015-08-19 2021-07-09 哈佛学院院长及董事 脂化psa组合物和方法
WO2018014012A1 (en) * 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
CN109481472A (zh) * 2017-09-11 2019-03-19 广州知易生物科技有限公司 脆弱拟杆菌提取物在制备防治炎症性肠病的药物或食品中的应用

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US3723506A (en) 1971-08-11 1973-03-27 Univ Sherbrooke Oxidation of sugars
DE2917104A1 (de) 1979-04-27 1980-11-06 Hoechst Ag Verfahren zur viskositaetserniedrigung von celluloseethern durch ozon und seine verwendung
JPS56128721A (en) 1980-03-12 1981-10-08 Eisai Co Ltd Antiallergic agent
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
JPS60501259A (ja) 1983-05-06 1985-08-08 ウイスコンシン・アルムニ・リサ−チ・フアンデ−シヨン 免疫刺激活性をもつ単糖類化合物
JPS618945A (ja) 1984-06-25 1986-01-16 Nec Corp 半導体集積回路装置
SE456346B (sv) 1984-07-23 1988-09-26 Pharmacia Ab Gel for att forhindra adhesion mellan kroppsvevnader och sett for dess framstellning
US4619995A (en) 1984-12-24 1986-10-28 Nova Chem Limited N,O-carboxymethyl chitosan and preparative method therefor
AU590599B2 (en) 1985-07-12 1989-11-09 New York University Immunogenic peptide antigen corresponding to plasmodium vivax circumsporozoite protein
US4684727A (en) 1985-07-29 1987-08-04 Schering Corporation Zwitterionic 1,8-naphthyridine and pyrazino[2,3-b]pyridine containing compounds useful as anti-allergic, anti-inflammatory and cycloprotective agents
AU7232087A (en) 1986-03-26 1987-10-20 Genexpress Aps Biological containment
US4775626A (en) 1986-05-23 1988-10-04 Syntex (U.S.A.) Inc. Method and compositions for protecting anerobic microorganisms
US4819617A (en) 1986-09-04 1989-04-11 University Of Florida Viscoelastic material for ophthalmic surgery
US5514581A (en) 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
DE3704389A1 (de) 1987-02-12 1988-08-25 Blutspendedienst Dt Rote Kreuz Verfahren zur herstellung von lymphokinen durch induktion lymphoider zellen
US4835252A (en) 1987-02-26 1989-05-30 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
US5215896A (en) 1987-03-20 1993-06-01 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
US6174999B1 (en) 1987-09-18 2001-01-16 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US4937270A (en) 1987-09-18 1990-06-26 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US5140016A (en) 1988-05-31 1992-08-18 University Of Florida Method and composition for preventing surgical adhesions using a dilute solution of polymer
US5126141A (en) 1988-11-16 1992-06-30 Mediventures Incorporated Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
DE3840044A1 (de) 1988-11-27 1990-06-07 Behringwerke Ag Glykosphingolipide mit kopplungsfaehiger gruppe im sphingoidanteil, ihre herstellung und verwendung
US5196510A (en) 1988-12-29 1993-03-23 Cytogen Corporation Molecular recognition units
FI895708A7 (fi) 1989-02-10 1990-08-11 Alko Ab Oy Vesiliukoinen hajoamistuote
US4952524A (en) 1989-05-05 1990-08-28 At&T Bell Laboratories Semiconductor device manufacture including trench formation
US5158939A (en) 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
RO111416B1 (ro) 1989-12-14 1996-10-31 Ca Nat Research Council Polizaharide modificate de neisseria meningitidis si e coli, combinatii antigenice si metoda de imunizare
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5130417A (en) 1990-04-30 1992-07-14 Washington University Entamoeba histolytical immunogenic protein and cdna clone
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
KR940006696B1 (ko) 1991-01-16 1994-07-25 금성일렉트론 주식회사 반도체 소자의 격리막 형성방법
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
GB2254083A (en) 1991-03-28 1992-09-30 Italfarmaco Spa Anticoagulants from e.coli saccharide
GR920100122A (el) 1991-04-05 1993-03-16 Ethicon Inc Πολυσακχαρίτες οι οποίοι περιέχουν καρβοξύλιο με σταυροειδείς δεσμούς δια την πρόληψιν της προσφύσεως.
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US5705178A (en) 1991-05-31 1998-01-06 Gliatech, Inc. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US20050181021A1 (en) 1992-02-14 2005-08-18 Robert Lamb Vitamin E phosphate/phosphatidycholine liposomes to protect from or ameliorate cell damage
US5350941A (en) 1992-09-23 1994-09-27 Texas Instruments Incorporated Trench isolation structure having a trench formed in a LOCOS structure and a channel stop region on the sidewalls of the trench
DE69330464T2 (de) 1992-09-24 2001-11-08 Brigham And Women's Hospital, Boston Gruppe b streptococcus typ ii und typ v polysaccharid-protein konjugate als impfstoffe
US5433794A (en) 1992-12-10 1995-07-18 Micron Technology, Inc. Spacers used to form isolation trenches with improved corners
US5728385A (en) 1993-08-12 1998-03-17 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
US5705335A (en) 1993-11-26 1998-01-06 Hendry; Lawrence B. Design of drugs involving receptor-ligand-DNA interactions
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
JPH07326664A (ja) 1994-05-31 1995-12-12 Fuji Electric Co Ltd ウエハの誘電体分離溝の充填方法
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5679654A (en) 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5700787A (en) 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
CA2204355C (en) 1994-11-02 2001-01-16 Gail Mandel Peripheral nervous system specific sodium channels, dna encoding therefor, crystallization, x-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof
US5858964A (en) 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
US5679658A (en) 1995-05-08 1997-10-21 Chitogenics, Inc. N,O-carbonxymethylchitosan for prevention of surgical adhesions
US5851808A (en) 1997-02-28 1998-12-22 Baylor College Of Medicine Rapid subcloning using site-specific recombination
JP2001519817A (ja) 1997-03-26 2001-10-23 ブリガム アンド ウイメンズ ホスピタル 糖断片生成法
ATE229038T1 (de) 1997-04-04 2002-12-15 Fidia Advanced Biopolymers Srl N-sulfatierte hyaluronsäureverbindungen, ihre derivate und verfahren zu ihrer herstellung
US6749831B1 (en) 1997-05-16 2004-06-15 Medical Defense Technology, Llc Vaccine against lipopolysaccharide core
US5929049A (en) 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
EP0908179A1 (en) 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
US6015787A (en) 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
EP1061949B1 (en) 1998-03-03 2009-07-15 University of Southern California Cytokines and mitogens to inhibit graft-versus-host disease
WO1999052560A1 (en) 1998-04-13 1999-10-21 Massachusetts Institute Of Technology Comb copolymers for regulating cell-surface interactions
ITPD980169A1 (it) 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
CA2366895A1 (en) 1999-04-02 2000-10-12 Brigham And Women's Hospital, Inc. Immunomodulating polymers
EP1459757A1 (en) 1999-04-02 2004-09-22 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US7083777B1 (en) 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
JP2001055335A (ja) 1999-08-18 2001-02-27 Toshio Sato アレルギー性皮膚疾患治療剤
US6995237B1 (en) 1999-10-27 2006-02-07 Cel-Sci Corporation Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
EP1303285A2 (en) 2000-07-17 2003-04-23 Chr. Hansen A/S Methods and formulations with probiotic microorganisms and medicaments
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US6670146B2 (en) 2000-10-04 2003-12-30 Schering Corporation Regulatory T cells; methods
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
WO2002055091A1 (fr) 2001-01-12 2002-07-18 Amato Pharmaceutical Products,Ltd. Agents antiallergiques
WO2002064110A2 (en) 2001-02-13 2002-08-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Carotenoid-loaded liposomes
EP1372706B1 (en) 2001-03-09 2010-12-01 ID Biomedical Corporation of Quebec Proteosome-liposaccharide vaccine adjuvant
US20050101012A1 (en) 2001-03-12 2005-05-12 Gerold Schuler CD4+CD25+ regulatory T cells from human blood
NZ530635A (en) 2001-06-15 2007-03-30 Nordic Vaccine Technology As Therapeutical vaccination comprising an immunogen and a targeting vehicle comprising a carrier and a antigen silmilar to the first
EP1308167A1 (de) 2001-11-06 2003-05-07 Pickl, Winfried, Ao. Univ. Prof. Dr. Antigenpräsentierende Vesikel
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
US20030147865A1 (en) 2002-02-07 2003-08-07 Benoit Salomon Cell therapy using immunoregulatory T-cells
DE60325696D1 (de) * 2002-02-22 2009-02-26 Ca Nat Research Council Synthese von lipopolysaccharid-protein konjugatvaccinen über die lipid-a region nach entfernung des glycosidischen phosphatresidüs
EP1494687A2 (en) 2002-03-08 2005-01-12 Eli Lilly And Company Immunomodulatory polymeric antigens for treating inflammatory pathogies
US7166455B2 (en) 2002-03-13 2007-01-23 The Brigham And Women's Hospital, Inc. Method for overexpression of zwitterionic polysaccharides
US7829289B2 (en) 2002-05-14 2010-11-09 Institut National De La Sante Et De Recherche Medicale T cell subpopulation regulating gut immunity
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
EP2272522B1 (en) 2002-06-28 2017-09-06 Nestec S.A. Therapeutic compositions for use in prophylaxis or treatment of diarrheas
CA2508720A1 (en) 2002-12-03 2004-06-17 Dartmouth College Method to measure a t cell response and its uses to qualify antigen-presenting cells
AU2004227852B2 (en) 2003-03-31 2010-01-14 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
US20060257852A1 (en) 2003-04-10 2006-11-16 Chiron Corporation Severe acute respiratory syndrome coronavirus
WO2005010215A2 (en) 2003-07-17 2005-02-03 Tolerrx, Inc. Methods for identifying tolerance modulatory compounds and uses therefor
US6846807B1 (en) 2003-07-25 2005-01-25 Board Of Regents, The University Of Texas System Colorectal neoplasia prophylaxis
AU2004267383A1 (en) 2003-08-14 2005-03-03 The Bio Balance Corporation Bacterial strains, compositions including same and probiotic use thereof
DE10353593A1 (de) 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
AU2004298983A1 (en) 2003-12-10 2005-06-30 Activbiotics, Inc. Rifamycin analogs and uses thereof
ATE539757T1 (de) 2004-11-02 2012-01-15 Univ Leland Stanford Junior Verfahren zur hemmung von nkt-zellen
US8426146B2 (en) 2005-06-03 2013-04-23 University of Pittsburgh—of the Commonwealth System of Higher Education Multiparameteric method for assessing immune system status
KR101300086B1 (ko) 2005-10-06 2013-08-30 프로비 아베 자가면역질환의 치료를 위한 락토바실러스의 용도
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
WO2007092451A2 (en) 2006-02-06 2007-08-16 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
CN100366737C (zh) 2006-03-01 2008-02-06 哈尔滨美华生物技术股份有限公司 固定化乳糖酶生产方法
WO2007106073A2 (en) 2006-03-02 2007-09-20 University Of Massachusetts Modified pathogens for use as vaccines
US20090252708A1 (en) 2006-05-18 2009-10-08 Biobalance Llc Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof
ES2686593T3 (es) 2006-05-31 2018-10-18 The Regents Of The University Of California Expresión de CD127 que correlaciona inversamente con FoxP3 y la función supresora de Treg CD4+
PT103495B (pt) 2006-06-05 2017-05-12 Faculdade De Farmácia Da Univ De Lisboa Pró-fármacos de ácidos orgânicos e composições farmacêuticas contendo os referidos pró-fármacos
EP2468300B1 (en) 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PT2126054T (pt) 2007-01-31 2016-10-12 Yeda Res & Dev Células t reguladoras geneticamente modificadas, redirecionadas e sua utilização na supressão de doenças inflamatórias e autoimunitárias
TW200904340A (en) 2007-05-11 2009-02-01 Mannatech Inc Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same
EP2165194A4 (en) 2007-05-31 2010-09-08 Abbott Lab BIOMARKERS FOR PREDICTING RESPONSABILITY TO TNF ALPHA INHIBITORS IN AUTOIMMUNE DISEASES
WO2009035738A2 (en) 2007-06-15 2009-03-19 University Of Rochester Use of antibody secreting cell elispot to assess antibody responses following antigen exposure
US8563523B2 (en) * 2007-09-07 2013-10-22 University Of Georgia Research Foundation, Inc. Synthetic lipid A derivative
US20090124573A1 (en) 2007-11-09 2009-05-14 Sarkis Mazmanian Immunomodulating compounds and related compositions and methods
US20110002965A1 (en) 2007-11-09 2011-01-06 Round June L Immunomodulating compounds and related compositions and methods
TWI468188B (zh) 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
FR2930264B1 (fr) 2008-04-18 2013-02-22 Gervais Danone Sa Nouvelle souche de lactobacillus paracasei subsp. paracasei dotee de proprietes antimicrobiennes et immunomodulatrices.
US8586029B2 (en) 2008-06-04 2013-11-19 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
WO2010025542A1 (en) 2008-09-05 2010-03-11 National Research Council Of Canada Lps based vaccines
US8911711B2 (en) 2008-09-30 2014-12-16 The Invention Science Fund I, Llc Method, device, and system to control pH in pulmonary tissue of a subject
EP2422200A4 (en) 2009-04-23 2013-02-27 California Inst Of Techn METHOD AND SYSTEMS FOR IDENTIFYING IMMUNOMODULATIVE SUBSTANCES
US20100311686A1 (en) 2009-06-03 2010-12-09 Kasper Lloyd H Nutraceutical composition and methods for preventing or treating multiple sclerosis
US8580278B2 (en) 2009-06-03 2013-11-12 Trustees Of Dartmouth College Nutraceutical composition and methods for preventing or treating multiple sclerosis
HUE040658T2 (hu) 2010-04-07 2019-03-28 California Inst Of Techn Vivõanyag vegyület mukózus membránhoz juttatásához és kapcsolódó készítmények, eljárások és rendszerek
WO2011146910A1 (en) 2010-05-20 2011-11-24 Round June L Antigen specific tregs and related compositions, methods and systems
CN102947441A (zh) 2010-06-01 2013-02-27 穆尔研究企业有限责任公司 来自拟杆菌属的细胞组分、其组合物和使用拟杆菌或其细胞组分的治疗方法
US20140030807A1 (en) 2010-07-20 2014-01-30 Trustees Of Dartmouth College Method for stimulating foxp3+ regulatory t cell expression of cd39
WO2012048152A2 (en) 2010-10-07 2012-04-12 Mazmanian Sarkis K Probiotic therapies for autism
US20130064859A1 (en) 2011-01-28 2013-03-14 Sarkis K. Mazmanian Combinatorial vitamin d and probiotic therapy for inflammatory bowel disease
US9539281B2 (en) * 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
WO2013019896A1 (en) 2011-08-01 2013-02-07 Symbiotix Biotherapies, Inc. Platform for identifying and/or characterizing immunomodulatory agents
EP2763540A4 (en) 2011-09-09 2015-04-22 Univ Yale COMPOSITIONS AND METHODS FOR THE EVALUATION AND TREATMENT OF INFLAMMATORY DISEASES AND DISEASES
EP2764090B1 (en) 2011-10-03 2017-12-13 California Institute of Technology Generation of psa-only producing mutant strain
US20140072534A1 (en) 2012-08-30 2014-03-13 California Institute Of Technology Novel therapy for multiple sclerosis using vitamin d and gut bacteria
WO2014182966A1 (en) 2013-05-10 2014-11-13 California Institute Of Technology Probiotic prevention and treatment of colon cancer
AU2014388299A1 (en) 2014-03-25 2016-10-20 The Government Of The United States Of America As Represented By The Secretary Of The Army Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines
CN108135167B (zh) 2015-08-19 2021-07-09 哈佛学院院长及董事 脂化psa组合物和方法
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use

Also Published As

Publication number Publication date
CN108135167A (zh) 2018-06-08
JP2018528303A (ja) 2018-09-27
US20190046560A1 (en) 2019-02-14
CN108135167B (zh) 2021-07-09
EP3337321A4 (en) 2019-07-17
US10857177B2 (en) 2020-12-08
CN113637040A (zh) 2021-11-12
CA2997211A1 (en) 2017-02-23
US20210315923A1 (en) 2021-10-14
EP3337321A1 (en) 2018-06-27
WO2017031431A1 (en) 2017-02-23
JP2021178967A (ja) 2021-11-18

Similar Documents

Publication Publication Date Title
US9539281B2 (en) Lipid-containing PSA compositions, methods of isolation and methods of use thereof
JP2021178967A (ja) 脂質化ｐｓａ組成物および方法
Peters et al. Arabinogalactan isolated from cowshed dust extract protects mice from allergic airway inflammation and sensitization
KR101573648B1 (ko) 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
AU2022201447B2 (en) Polysaccharide compositions and methods of use
JP2013010789A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染に対する多糖類ワクチン
US6534648B1 (en) Isolated algal lipopolysaccharides and use of same to inhibit endotoxin-initiated sepsis
JP5490341B2 (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染のための多糖ワクチン
US20230130767A1 (en) Glycolipid compositions and methods of use
CA2997211C (en) Lipidated psa compositions and methods
JP7092308B2 (ja) リピドａ
US11078257B2 (en) Recombinant gram negative bacteria and methods of generating and utilizing same
Cheng Development of alkyl imidate glycosylation method and application to allyl Lewis A synthesis
WO2004037272A1 (ja) デング熱ウィルス感染阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210615

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210714

R150 Certificate of patent or registration of utility model

Ref document number: 6918365

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees